Understanding and conquering major depression: biology and tools

Executive overview

Major depression affects 5% of the population and ranks as the fourth leading cause of disability worldwide. Three neurotransmitter systems — norepinephrine, dopamine, and serotonin — each drive distinct symptom clusters: lethargy, anhedonia, and grief respectively.

Effective interventions target the same biochemical pathways as prescription antidepressants. Inflammation is a central, underappreciated driver that can be addressed through diet, exercise, and supplementation.

The core insight: depression is a biological disorder with multiple overlapping chemical systems, and behavioural and nutritional interventions operate on the same pathways as drugs.

Symptoms of major depression

• Anhedonia: flat affect, inability to experience pleasure
• Anti-self confabulation: delusional negative self-narration that doesn't match reality
• Vegetative symptoms: chronic exhaustion, disrupted sleep architecture, early waking (3–5 a.m.)
• Cortisol dysregulation: peak shifts to ~9 p.m. instead of morning
• Decreased appetite; hormonal disruption (thyroid, cortisol)

Neurochemistry: three systems, three symptom clusters

• Norepinephrine deficit → psychomotor lethargy, inability to get out of bed
• Dopamine deficit → anhedonia, loss of motivation and pleasure-seeking
• Serotonin deficit → grief, guilt, emotional dysregulation
• SSRIs increase synaptic serotonin efficacy; work for ~two-thirds of patients; effects appear ~2 weeks after starting
• Tricyclics and MAO inhibitors raise norepinephrine; effective but significant side effects
• Clinical reality: systems interact; good psychiatry involves tuning multiple pathways

Hormonal and genetic risk factors

• 20% of people with major depression have low thyroid hormone
• Postpartum, menstrual cycle, and menopause all increase depression risk via hormonal shifts
• Chronic stress raises cortisol, which suppresses dopamine, norepinephrine, and serotonin synthesis
• Identical twin concordance ~50%; fraternal twins ~25%; half-siblings ~10% — strong genetic component
• Genetic predisposition makes stress management especially important as a preventive measure

Inflammation as a root mechanism

• Chronic inflammation elevates cytokines (IL-6, TNF-alpha, C-reactive protein)
• Cytokines divert tryptophan away from serotonin synthesis toward quinolinic acid — a neurotoxin
• Quinolinic acid is pro-depressive; this explains why inflammation worsens mood at a biochemical level
• Exercise sequesters kynurine into muscle, blocking its conversion to the neurotoxin

Behavioural and nutritional tools

• Exercise: raises norepinephrine, dopamine, and serotonin; diverts tryptophan toward serotonin; directly counters inflammatory pathway
• Cold exposure: deliberate cold showers reliably spike norepinephrine and epinephrine
• EPA omega-3s: 1,000–2,000 mg/day of EPA (not just total omega-3) reduces inflammatory cytokines and can lower the required SSRI dose
• Creatine monohydrate: augments SSRI response; supports forebrain phosphocreatine system involved in mood and reward; evidence especially in women with MDD
• Ketogenic diet: shifts brain metabolism to ketones, increases GABA activity, may help treatment-refractory depression

Emerging clinical treatments

• Ketamine: creates dissociative states that distance patients from grief; may induce neural plasticity that reduces emotional weight of depression
• Psilocybin: acts at 5-HT2A serotonin receptors; a 2021 JAMA Psychiatry RCT found 50–70% significant improvement in MDD patients; rewires associations between emotional events regardless of subjective experience content
• Severe depression often prevents people from accessing behavioural tools — pharmacological intervention may be necessary to restore enough function to engage non-drug approaches